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Original Article
Non-Invasive Monitoring of Oxygen
Tension and Oxygen Transport Inside
Subcutaneous Devices After
H2S Treatment
Avid Najdahmadi1 , Alexandra M. Smink2, Paul de Vos2,
Jonathan R.T. Lakey3,4 , and Elliot Botvinick1,3,4
Abstract
Medical devices for cell therapy can be improved through prevascularization. In this work we study the vascularization of a
porous polymer device, previously used by our group for pancreatic islet transplantation with results indicating improved
glycemic control. Oxygen partial pressure within such devices was monitored non-invasively using an optical technique.
Oxygen-sensitive tubes were fabricated and placed inside devices prior to subcutaneous implantation in nude mice. We tested
the hypothesis that vascularization will be enhanced by administration of the pro-angiogenic factor hydrogen sulfide (H2S). We
found that oxygen dynamics were unique to each implant and that the administration of H2S does not result in significant
changes in perfusion of the devices as compared with control. These observations suggest that vascular perfusion and density
are not necessarily correlated, and that the rate of vascularization was not enhanced by the pro-angiogenic agent.
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Introduction
Tissue engineering approaches to create bioartificial organs
have been emerging in the past few decades1,2. In the case of
the pancreas, as related to endocrine function, evidence sug-
gests that it is unnecessary to replace the whole organ. It is
shown that transplantation of the islets of Langerhans that
contain the endocrine cells also results in restoration of the
endocrine function3. For example, transplantation of isolated
pancreatic islets is used to treat type 1 diabetes (T1D). T1D
is caused by autoimmune destruction of pancreatic beta
cells4. These cells normally synthesize and secrete insulin,
which is an important hormone involved in physiological
regulation of blood glucose. Self-monitoring of blood glu-
cose (by lancet blood draw and glucose meter) in conjunc-
tion with multi-daily injections of insulin is the standard of
care. However, the resulting glycemic control is imperfect
and can cause harmful secondary complications such as car-
diovascular diseases, retinopathy, and nephropathy5–7. A
promising alternative to daily insulin injections is transplan-
tation of pancreatic islet cells. This transplantation can pro-
vide autonomous regulation of blood glucose concentration
and therefore result in stable glycemic control, thus
preventing secondary complications8. Islet transplantation
into the portal vein has resulted in insulin independency in
the first year; however, the insulin independency was shown
to decrease to less than 50% after 5 years9,10. These findings
support the potential for pancreatic islets to treat T1D; how-
ever, in consideration of the 5-year half life, inaccessibility
for islet retrieval, and risk to the liver, better approaches are
needed.
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Polymer devices for housing islets are being developed to
improve the outcomes of islet transplantation. A variety of
polymer systems as well as implantation sites have been
investigated11–17. Literature suggests that the subcutaneous
space can be advantageous for cellular transplantation
because of ease of access and less invasive surgical proce-
dures, but because of low oxygen tension and vasculariza-
tion under the skin, hypoxia can occur18,19. Hypoxia can
induce apoptosis and necrosis and ultimately compromise
the functionality of transplanted cells20. Multiple groups
have shown that islet transplantation under the skin can be
successful after modulation of the site with a device21,22.
Critical to the success of these devices is adequate supply
of oxygen, which can be provided if sufficient vascular per-
fusion is introduced. Such perfusion can be stimulated by
using microporous structures23, inclusion of angiogenic fac-
tors24, co-transplantation of vascular inductive cell types, or
devices that can be implanted for prevascularization prior to
transplantation of the cells25. A well-vascularized device
will provide reduced diffusional distances between the
newly formed vasculature and the transplanted cells and
result in faster transport dynamics of nutrients and oxygen,
preventing the loss of cells by hypoxia. We have developed a
porous poly(D, L-lactide-co-e-caprolactone) (PDLLCL)
polymer scaffold that has shown successful results in pro-
moting islet-cell survival and achieving normoglycemia
under the skin of athymic nude mice for the duration of a
70 day study26. This porous scaffold is designed for inducing
vascularization in vivo and can potentially compensate for
loss of perfusion through the interpenetrating islet capillary
network following isolation. Our previous results26 suggest
that further increasing the vascularization of these devices
may lead to a faster return to normoglycemia with lower
number of islets.
In this study, we investigated hydrogen sulfide (H2S) as
an agent to improve vascularization of the PDLLCL device.
H2S is a gaseous signaling molecule, like nitric oxide and
carbon monoxide, normally produced by the body. It was
first described as a neuromodulator27, but was later recog-
nized for its effects on vascular cells28. Endogenous H2S is
enzymatically generated in vascular cells, where it exhibits
vasoactive, anti-oxidant, anti-inflammatory, and anti-
apoptotic properties28. The effects of H2S are well described,
but the molecular pathways of its action are poorly under-
stood. Cai and coworkers were the first to show that intra-
peritoneal injections of the exogenous H2S donor NaHS
stimulate angiogenesis in subcutaneous Matrigel plugs in
mice29. Increased angiogenesis was shown by higher hemo-
globin levels and the presence of more capillaries with NaHS
administration at concentrations of 10 and 50 mmol/(kg*d) as
compared with the untreated group. Here we investigate
whether H2S will have a similar effect on vascularization
of our PDLLCL devices implanted into the subcutaneous
compartment as assessed by histology, CD31 expression,
and an optical measure of oxygen transport between vascu-
lature and the device.
Materials and Methods
Device Preparation
Devices were obtained from Polyganics B.V. (Groningen,
The Netherlands). A 4% (w/v) PDLLCL solution was pre-
pared in chloroform (Sigma-Aldrich, Zwijndrecht, The
Netherlands). The PDLLCL solution was thoroughly mixed
with natriumchloride particles (Sigma-Aldrich, Zwijndrecht,
The Netherlands) of 250–425 mm (10:1 w/w) in order to
create a porous structure. This solution was transferred into
sterile glass Petri dishes to allow the solvent to evaporate. To
remove the salt particles, the polymer sheet (5 mm thick)
was extensively washed with sterile H2O. The polymer sheet
was casted and resized, resulting in a 10 mm by 15 mm
device. During the casting process three channels were cre-
ated by introducing 400 mm diameter iron rods. These chan-
nels were created to accommodate cells, and in the current
study they were used for insertion of the oxygen-sensitive
tubes (OSTs) to non-invasively monitor the oxygen tension
in vivo (Fig. 1A). The scaffolds were stored in 70% ethanol
for several days to sterilize the scaffolds before implantation.
OST Fabrication
OSTs comprise an oxygen-permeable tube and an oxygen-
sensitive dye. The selected oxygen-sensitive dye is platinu-
m(II)- meso-tetra (4-fluorophenyl) tetrabenzoporphyrin
(PtTPTBPF), which has peak absorptions at 430 and 614
nm and emission peak at 773 nm (Frontier Scientific, Logan,
UT, USA). This dye was mixed with polystyrene (MW 2500,
Sigma, St. Louis, MO, USA) and dissolved into a solution
using chloroform (Sigma, St. Louis, MO, USA), to form the
dye solution. The dye solution contains 4 mg PtTPTBPF, 60
mg polystyrene and 900 mL chloroform. The dye solution
was flushed through an oxygen-permeable biocompatible
silicone tubing (BTSIL-037, Instech Laboratories, Plymouth
Meeting, PA, USA) five times to form a homogenous inner
coating of PtTPTBPF inside the silicone tubes. The tubes
were stored in a well-ventilated dark environment at 24C
for a duration of 24 h to allow the remaining chloroform to
evaporate. A stainless steel wire (24 Gauge A1 Wire,
Kanthal, Sweden) was then inserted into each tube in order
to provide mechanical stability (Fig. 1B). Afterwards the
tubes containing a wire were cut to a length matching the
PDLLCL device (15 mm) and the ends were sealed using
medical-grade silicone adhesive (MED-1000 Nusil, Carpin-
teria, CA, USA). The sealed tubes were kept at room air in a
dark environment for 2 days to fully cure. OSTs were ster-
ilized by immersion in 70% ethanol for 12 h.
The Oxygen Monitor
An oxygen monitor was fabricated a previously described30.
The monitor is placed onto the surface of skin, emits light
through the skin and onto the implanted OSTs, and receives
luminescence to record luminescent waveforms. The
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monitor comprises a printed circuit board that houses a sili-
con photodetector bracketed by two light-emitting diodes
(LEDs) having central emission wavelength of 617 nm (Fig.
1C). An optical bandpass filter is mounted onto the detector
to reject the LED wavelengths while passing the dye emis-
sion wavelengths. For each oxygen measurement both LEDs
flash simultaneously 25 times at 1% duty cycle (100 ms on,
10,200 ms off) to excite the oxygen-sensitive porphyrin dye.
The emission of the dye after each flash is passed through an
optical filter and onto the photodiode. Photodiode electrical
current is converted to voltage by an operational amplifier
and sampled over a period of 200 ms at a sampling frequency
of 500 kHz using a myRIO data acquisition module
(National Instruments, Austin, TX, USA). LED and data
acquisition timing is controlled by LABVIEW 2015
(National Instruments, Austin, TX, USA). The dye continues
to emit light after the end of each LED emission period with




where V is the detector voltage, V0 is the voltage at the start
of the decay, t is time in seconds, t is the lifetime parameter
reported in seconds. Lifetime values were computed from
emission waveforms using the fit function in MATLAB
(MathWorks, Natick, MA, USA) configured for nonlinear
least squares regression. The average t for all 25 cycles is
hereafter reported as lifetime (t). The porphyrin dye emis-
sion is quenched by oxygen and consequently lifetime values
(t) decrease with increasing PO2.
OST Calibration
A custom-built glass chamber with an inlet and outlet port
was placed above the oxygen monitor. OST were individu-
ally placed inside the chamber and exposed to different gases
mixtures at atmospheric pressure comprising 160), 76, 38,
and 0 mmHg oxygen. t was measured at each oxygen partial
pressure to generate a calibration curve (Fig. 2A). This pro-
cess is repeated for each OST individually. OSTs were
matched for calibration in groups of three and inserted into
devices.
Implantations and NaHS Injections in Animals
The University of California Institutional Animal Care and
Use Committee at the University of Irvine approved all
described animal procedures (IACUC # 2008-2850). Animals
were housed at the University of California Irvine animal
facility and maintained under 12-hour light/dark cycles with
ad libitum access to water and standard chow. Devices were
implanted in male athymic nude mice (Foxn1nu, Charles
Figure 1. (A) Oxygen-sensitive tubes (OSTs) shown as green cylinders (15 mm in length) are inserted into three empty channels of the
porous PDLLCL device (5 mm  10 mm  15 mm) to quantify oxygen tension. (B) OSTs act as retrievable oxygen-monitoring sensors and
are made of oxygen-permeable silicone tubing coated on the inner surface with a layer of PtTPTBPF and reinforced with stainless steel wire.
Both ends are sealed using medical-grade silicone adhesive. (C) Oxygen monitor comprising a printed circuit board that houses two LEDs,
photodetector and optical filter.
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River, Wilmington, MA, USA) 8 weeks old. Briefly, under
anesthesia a small incision was made in the skin to create a
subcutaneous pocket on the back of the mouse. PDLLCL
devices containing the calibrated OSTs and fibrin were placed
into this pocket and the skin was closed using skin staples
(Cellpoint Scientific, Gaithersburg, MD, USA). All mice
received ibuprofen water (0.2 mg/mL; Banner Pharmacaps,
High Point, NC, USA) as analgesic post-surgery for 2 days.
Since H2S is a gas, we used a sodium hydrosulfide (NaHS)
solution as a H2S donor. NaHS is unstable in solution and
therefore a new solution was prepared just prior to each injec-
tion. From the day of implantation, mice received twice daily
an intraperitoneal injection of NaHS until 28 days after
implantation. One group of mice (n ¼ 6) received a low dose
of NaHS (25 mmol/kg), the other group (n ¼ 6) received a
high dose of NaHS (50 mmol/kg), and mice receiving saline
injections served as a control group (n ¼ 6).
Dynamic Inhaled Gas Test (DIGT)
To closely follow the vascularization process in vivo, DIGT
measurements were performed on days 3, 7, 21, 35, 49 and
63 after implantation on each animal (n ¼ 6 per group). For
the DIGT measurements each mouse was anesthetized by 2–
3% of isoflurane (Piramel Healthcare, Morpeth, United
Kingdom) while breathing 760 mmHg oxygen. When the
animals were under full anesthesia the gas was changed to
152 mmHg oxygen and isoflurane level was reduced to
1.5%. The optical monitor was then placed on the skin
directly above the implanted device. Following 100 baseline
lifetime measurements (spaced by 4.25 s for a total of 425 s),
the inhaled gas was switched back to 760 mmHg oxygen. It
is expected that the tissue PO2 will rise and fall as the inhaled
PO2 is increased and decreased, respectively. Accordingly,
once the inhaled gas is returned to 760 mmHg, lifetime
values should reach a new plateau, where the time to plateau
is an indication of the oxygen transport between the blood,
tissue and OSTs. Once the plateau was reached, animals
were taken off of anesthesia and returned to their cages. The
time to plateau is calculated using custom MATLAB code
(MathWorks, Natick, MA, USA) and reported here as Rise-
time (in minutes).
Vessel Morphology
The subcutaneous devices were removed on day 63 after
implantation. OSTs were removed from the devices and
devices were cut into two pieces; one half of the scaffold
was processed for the histological analysis whereas the other
half was used for the quantification of vessels by PCR
(described below). For histology, the scaffolds were fixated
in 2% paraformaldehyde and processed for paraffin embed-
ding. Sections were stained with an overnight incubation of
CD31 (1:200; R&D Systems, Abingdon, United Kingdom)
after 15 min incubation at 100C for antigen retrieval (10
mM citrate buffer, pH 6.0) and a subsequent blocking step
with 5% donkey serum (Sigma-Aldrich, Zwijndrecht, The
Netherlands). The secondary donkey anti-goat alkaline phos-
phatase conjugated antibody (1:100; Abcam, Cambridge,
United Kingdom) was applied for 45 min. Alkaline phospha-
tase activity was demonstrated by incubating for 10 min with
SIGMAFASTTM Fast Red (Sigma-Aldrich, Zwijndrecht,
The Netherlands). A short incubation with hematoxylin was
used as counterstain. All stained sections were scanned with
Figure 2. (A) Three calibration cycles of a single oxygen-sensitive tube (PO2: 160, 76, 38, and 0 mmHg, in order). Average lifetime values for
each plateau (at each gas mixture) across the three cycles are 19.0 + 0.07, 21.6 + 0.08, 24.9 + 0.04 and 34.1 + 0.06 ms, respectively. (B)
DIGT performed on an animal 3 days after device implantation. Risetime is defined as elapsed time between exchanging inhaled gas from 152
to 760 mmHg (left green circle) and steady state (right green circle).
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the microscope scanner Hamamatsu Nanozoomer (Hama-
matsu, Almere, The Netherlands). Scans were analyzed
using Aperio ImageScope (Leica Microsystems B.V., Rijs-
wijk, The Netherlands). The number of CD31-positive struc-
tures was normalized by the measured scaffold area (mm2).
The fold change was calculated relative to the control.
Vascularization Quantification
To quantify the amount of vessels in the scaffolds, half of the
scaffold at day 63 was processed for real-time reverse tran-
scription polymerase chain reaction (RT-PCR) for the vas-
cularization marker CD31. RNA was isolated using Trizol
according to the manufacturer’s protocol (Invitrogen, Fisher
Scientific, Landsmeer, The Netherlands). The RNA concen-
tration was determined using a NanoDrop 1000 spectrophot-
ometer (NanoDrop products, Wilmington, DE, USA). cDNA
was reverse transcribed using a SuperScript® III Reverse
Transcriptase kit according to the instructions of the manu-
facturer (Life Technologies, USA). RT-PCR was conducted
using ViiATM Real Time PCR system (Life technologies,
Carlasbad, CA, USA) with a primer and probe set (TaqMan
Gene Expression Assays, Thermo Fisher Scientific, USA)
for CD31 (Mm01242576_m1; Thermo Fisher Scientific,
Waltham, MA, USA) and qPCR Mastermix Plus (Eurogen-
tec, Seraing, Belgium). Reactions were performed at 50C
for 2 min, 95C for 10 min, 95C for 15 s and 60C for 60 s
repeating in these last two steps for 40 cycles. Delta Ct
values were calculated and normalized against the expres-
sion of the housekeeping gene GAPDH (Mm99999915_g1;
Thermo Fisher Scientific, Waltham, MA, USA). Delta Ct
values were used to calculate the fold change compared with
gene expression of the control mice.
Statistics
Statistical analysis was carried out in GraphPad Prism (ver-
sion 7.0d; GraphPad Software, Inc., San Diego, CA, USA).
A Shapiro–Wilk normality test was performed to test the
data for normality. A Kruskal–Wallis test with Dunn’s mul-
tiple comparison was performed to study the statistically
significant differences for nonparametric distributions.
One-way ANOVA with a Tukey post-hoc was performed for
parametrically distributed data. p-values <0.05 were consid-
ered significant. The data are presented in mean + standard
deviation in case of parametric distribution and median +
interquartile range in case of nonparametric distribution.
Results
OST Calibration and DIGT
Prior to implantation, each OST (Fig. 1B) undergoes a gas
calibration inside a glass chamber. In this calibration gases
with different oxygen levels are inserted into the chamber in
order. Fig. 2A shows a calibration process during which the
gas mixtures were cycled three times. With each gas
exchange, the corresponding t is recorded as the mean value
of the subsequent plateau. Lifetime values at each oxygen
concentration across all three cycles show low variation
(standard deviation < 0.08 ms). This result demonstrates the
repeatability and reliability of oxygen measurements using
OST. Following the calibrations, OSTs were inserted into
devices, which were implanted as described above. Fig. 2B
shows an example of the calculated PO2 values during a
DIGT test. This curve demonstrates an increase in PO2 levels
as reported by the OSTs.
Animal Study
Animals received injections of NaHS (low and high-dosage
groups of 25 mmol/kg and 50 mmol/kg) and saline (control
group) as described above. Injections occurred twice daily for
the first 4 weeks (day 28) followed by another 5 weeks of no
injections (up to day 63). The follow-up period of 5 weeks
with no injections (day 28 to day 63) aims to provide neces-
sary time for device vascularization to complete. The DIGT
was performed on all animals (n ¼ 6 per group) on days 3, 7,
21, 35, 49, and 63. Fig. 3 (A–C) shows the Risetime values
calculated from the DIGT measurements on all animals. Sta-
tistical differences in lifetimes values were not observed either
for each treatment condition across all days, or between treat-
ment conditions on each day. Similarly, DIGT plateau oxygen
pressures do not show statistical differences or trends between
different conditions or at different timepoints (Fig. 3 (D–F)).
These observations indicate vascular perfusion of implants
was not affected by administration of the pro-angiogenic
H2S. Fig. 4 shows the histological and gene expression eva-
luations performed on the explanted devices (explantation on
day 63). Surprisingly, statistically different values were
observed for the expression of the endothelial cell marker
CD31 between treatment groups (Fig. 4D). This may indicate
that treatment with a low dose of H2S can possibly down-
regulate the gene expression of CD31 (fold change of 0.57
+ 0.02) compared with the control group and the high-dose
group. In addition, histological analysis of CD31 expression
shows a similar trend at the protein level (Fig. 4E). Here,
CD31-positive vessels were counted in each sample. While
the control mice had a mean vessel area density of 40.5 + 7.5
blood vessels per mm2 of scaffold, both the low and high
treatment groups showed significantly decreased values of
15.0 + 2 and 18.7 + 8.3 blood vessels per mm2 of scaffold,
respectively. These results indicate that the vascularization
inside the devices may have been negatively affected by the
H2S administrations.
Discussion
The success of subcutaneously implanted cell therapy
devices depends on the ability to transfer nutrients and oxy-
gen to implanted cells. It is shown that implantation of such
devices can trigger a series of host reactions at the implanta-
tion site, such as chronic inflammatory response, granulation
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tissue development, foreign body reaction, and fibrosis and
fibrous capsule development31–36. The foreign body
response often occurs in the first 3 weeks after implantation;
after which, wound healing may proceed accompanied with
neovascularization of the device36. Invariably, this foreign
body reaction can cause formation of diffusional barriers that
result in lower availability of nutrients and, importantly,
oxygen within the implanted devices. This low availability
can result in reduced functionality of the cells and formation
of hypoxic conditions, which ultimately can lead to cell
death and device failure37. It is therefore necessary to ensure
the availability of oxygen and nutrients as delivered by a
perfused vasculature. For such vascularization purposes,
porous three-dimensional biomaterials have been used as
subcutaneous medical devices in the field of tissue engineer-
ing22,23,26,38. The pore structure of these biomaterials allows
blood vessel infiltration and thereby reduction of diffusional
distances and barriers between the neovasculature and the
cells. In this study we explore the rate of vascularization and
oxygen availability inside porous PDLLCL devices devel-
oped by our group26,39. These PDLLCL devices have already
shown success in preserving functionality of pancreatic islet
cells after subcutaneous implantation, which resulted in
achieving normoglycemia in type 1 diabetic animals26,39.
In these previous studies we implanted the devices several
weeks before islet transplantation to allow dampening of the
foreign body response and ingrowth of blood vessels. When
islets were transplanted into these devices, the vasculariza-
tion supports functional islet survival in the period between
transplantation and islet revascularization. However, further
improving the vascularization of this device will lead to
faster induction of normoglycemia with lower numbers of
islets making islet transplantation available for a larger num-
ber of type 1 diabetic patients.
H2S has previously been shown to stimulate endothelial
proliferation and migration as well as the development of a
new vasculature within Matrigel constructs implanted sub-
cutaneously29. Our results from the non-invasive optical
measurements to assess device perfusion in vivo showed
no significant differences between the control and
H2S-administered groups over the 63-day period of the
study. Interestingly, histological and gene expression analy-
sis indicate that H2S administration may have resulted in
lowered formation of neovasculature, an observation not
reflected in oxygen dynamics between treatments groups and
across days. This suggests that any differences in the extent
of vascularization may not be large enough to elicit obser-
vable changes in oxygen transport dynamics. The vascular
Figure 3. (A–C) DIGT Oxygen Risetime (minutes) and (D-F) PO2 plateau value (mmHg) at the end of each DIGT experiment, measured for
three groups: control (saline), low (25 mmol/kg body weight) and high (50 mmol/kg body weight) NaHS dosages (n¼ 6 per group). All groups
underwent twice daily injections for the first 28 days followed by 35 days without injections (day 28 to 63). No statistical differences in
Risetime or PO2 plateau values were detected between groups.
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density as quantified with histology and CD31 expression
does not necessarily have to correlate with the DIGT signal,
as vascular density does not necessarily reflect the perfusion
of the device. For example, consider a cross-sectional view
of an oxygen-sensitive rod and its surrounding porous device
and tissue. There is a no-flux condition at the tube surface
(oxygen is not consumed by the dye) and PO2 dynamics
reported by the tubes are dependent upon (1) diffusional
properties of the tissue and device, which do not change at
the time scale of a DIGT, and (2) the net rate of transport of
oxygen from the vasculature into the device or tissue. These
changes are rapid, and depend on PO2 within the vasculature
and blood velocity within them. All things being equal, the
primary determinants of DIGT dynamics are total available
perfused vessel area, partial pressure of oxygen in the local
microvasculature, and tissue or device diffusional properties.
We can reliably assume that as vessels invade the device, the
system will take less time to reach a new steady state.
Accordingly, we anticipate Risetime would decrease with
increased vessel density and perfusion within the device.
In this study, as shown in Fig. 2B for day 3, the PO2 values
rise approximately up to 20 mmHg during the DIGT. These
oxygen measurements are exclusive to the surface of OSTs
and do not directly measure oxygen partial pressure else-
where in the device. The observed values are different from
what our group has previously reported for DIGT experi-
ments wherein alginate microcapsules containing oxygen-
sensitive microparticles were implanted subcutaneously in
Sprague-Dawley rats30. PO2 levels changed from 45 to 120
mmHg during a day-9 DIGT, at a rate approximately twice
that of the present study. These differences indicate that
spherical alginate capsules may make for a better environ-
ment for delivering oxygen as compared to the investigated
device.
In addition to slow dynamics, DIGT experiments reveal
low levels of oxygenation within devices measured at the
surface of the inserted OSTs. Importantly, our experiment
was designed to include six mice per condition, a number
estimated to be sufficient when we analyzed perfusion data
(total Hb) in the Cai et al. paper. However, DIGT data indi-
cate that six mice is not nearly enough to achieve statistical
power at a 95% level of confidence. A Monte Carlo simula-
tion based on observed mean and standard deviations in PO2
concludes that as many as 20 times more mice would be
required. Clearly any H2S effects are small, and any detect-
able statistical significance will not translate to benefits to
islet transplantation.
Further, our results indicate that the potentiation of vas-
culature growth and increased perfusion by administration of
H2S in Matrigel
29 is not observed for the PDLLCL devices.
A previous study by Cai et al. (2007) showed improved
angiogenesis in a Matrigel plug after 7 days of intraperito-
neal injections of NaHS29. We treated our mice for 28 days
with NaHS, indicating that long-term treatment with H2S
Figure 4. Histological analysis of blood vessels after 63 days of implantation. Blood vessels in the control (A), low H2S dosage (B), and high
H2S dosage (C) treated groups were stained by using the endothelial cell marker CD31 (pink color). (D) Gene expression of the endothelial
cell marker CD31 after 63 days of implantation and (E) the number of vessels per area (mm2) in each device was measured. Data is plotted as
mean with the standard error of mean. Statistical analysis was carried out using a one-way ANOVA with a Tukey post-hoc test, p < 0.05 (*)
and p < 0.001 (**).
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might not significantly affect the vascularization. Further,
Dufton et al.40 suggest that the administration of hydrogen
sulfide using NaHS can result in an increased inflammatory
response and triggering of TNF-a formation. Such inflam-
matory response caused by the injections during the first
4 weeks of implantation, which is also accompanied by
foreign body response, may then result in hampering the
reported pro-angiogenic characteristics of the H2S.
In summary, we show that the subcutaneously implanted
PDLLCL devices become vascularized in such a way that is
resistant to improved vascularization via H2S treatment.
However, we have used similar devices in pancreatic islet
implantation studies showing maintenance of islet function
with partial or total reversal of chronic hyperglycemia. This
may indicate that material properties of the PDLLCL, device
geometry, and pore characteristics play roles in governing
vascularization, a hypothesis supported by our previous
work and consistent with current thinking in the area of
biomaterials. Importantly, because our technology can sus-
tain islet function without the need for pharmaceutical fac-
tors, it may be categorized as a drug-independent device,
which is preferable as a medical product for regulatory
agencies.
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